All In Biotech

Drug Trial Radar · NCT06982651

A Study on the Safety, Pharmacokinetics, and Food Effects of MI078 Capsules

A Randomized, Double-Blind, Placebo-Parallel-Controlled Phase Ⅰ Clinical Trial of the Tolerability, Safety, Pharmacokinetics and Food Effects of MI078 Capsules in Single and Multiple Doses in Healthy Chinese Subjects

Last checked: Nov 19, 2026Latest source record: May 21, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

98

Actual

Start

Sep 9, 2023

Primary completion

Mar 18, 2024

Study completion Mar 18, 2024

Sponsor

Sponsor type
Industry
First posted
May 21, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study was divided into three studies, namely, a single administration study, a food impact study, and a multiple administration study.

Conditions

  • Postpartum Depression

Interventions

  • MI078Drug

    Dosage Form: Capsule Specification: 25 mg Administration and Dosage: Oral. 1 capsule per dose, once daily. Duration of Treatment: 1 day Dosage Form: Capsule Specification: 50 mg Administration and Dosage: Oral. 1 capsule per dose, once daily. Duration of Treatment: 1 day Dosage Form: Capsule Specification: 200 mg Administration and Dosage: Oral. Options include: * 1 capsule per dose, once daily; * 2 capsules per dose, once daily; * 3 capsules per dose, once daily; * 4 capsules per dose, once daily; Duration of Treatment: 1 day . Dosage Form: Capsule Specification: 200 mg Administration and Dosage: Oral. Options include: * 1 capsule per dose, twice daily; * 2 capsules per dose, twice daily; Duration of Treatment: 7 days . Dosage Form: Capsule Specification: 50mg Administration and Dosage: Oral. Options include: \- 5 capsule per dose, Three times a day Duration of Treatment: 3 days .

  • PlaceboDrug

    Placebo of MI078 Capsule

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence, severity, and causality of AEs, SAEsTime frame: up to 72 hours after the last dose
  2. vital signsTime frame: up to 72 hours after the last dose
  3. SpO₂Time frame: up to 72 hours after the last dose
  4. 12-lead electrocardiogram (ECG)Time frame: up to 72 hours after the last dose
  5. Modified Observer's Assessment of Alertness and Sedation Scale(MOAA/S)Time frame: up to 72 hours after the last dose
  6. Stanford Sleepiness Scale (SSS)Time frame: up to 72 hours after the last dose

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Third Xiangya Hospital, Central South University

    Changsha, Hunan, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.